Tag: Enzolytics

After dropping -2.38% in the last session, Enzolytics Inc (OTCPINK: ENZC) closed the last session at $0.2010, bringing its market cap to $562.39M. Enzolytics stock recently traded 42.22M shares, higher than the average daily volume of 41.93M. In addition, the shares have traded between $0.1821 and $0.2289. There are 2.80 billion outstanding shares compared to a float of 1.88 billion.

As measured by performance, ENZC stock performed -27.44% last week and 57.40% last month. While the quarterly performance fell by 33.07 percent, the annual performance improved by 51.85 percent with a 215.05% six-month performance. ENZC stock prices ranged from $0.0002 – $0.9580 in the past 52 weeks. Despite announcing progress in clinical trials, ENZC stock dropped.

What was the purpose of those clinical trials?

Enzolytics is a pharmaceutical company dedicated to the development and commercialization of proprietary proteins and monoclonal antibodies to treat disease caused by debilitating infectious agents. A number of therapeutics are being developed by ENZC for the treatment of infectious diseases. Among the ENZC’s patented and clinically tested compounds, ITV-1 (Immune Therapeutic Vaccine-1) contains l-inactivated pepsin fraction (IPF) that has been shown effective in treating HIV/AIDS.

A strategy by Enzolytics to advance its previously tested anti-HIV therapeutic ITV-1 to clinical trials and widespread distribution in Europe has been finalized.

• ENZC will achieve a significant milestone for both human health and profitability when these steps are completed for its anti-HIV therapy.
• An anti-HIV therapeutic developed by ENZC earlier made progress toward Bulgarian Drug Agency (BDA) certification, however that process was interrupted before it was completed.
• A significant number of positive results from clinical trials were nevertheless documented during that period.
• ENZC has no doubt that the clinical trials under the European Medicines Agency (EMA) will similarly succeed as a result of these positive results

How ENZC will go through it?

International Medical Partners Ltd. (IMPL) was formed by Enzolytics (ENZC) and European-based partners. IMPL is owned equally by ENZC and its partners and has the licenses to distribute the ITV-1 therapeutic in the 27 European countries covered by the European Medical Agency including Russia and its ex-Soviet states.

For the initial production of ITV-1, ENZC engages Danhson Ltd., a Contract Manufacturing Company (CMO) for use in preparing the Best Methods Report for future production and clinical trial documentation.

The stock of Enzolytics Inc (OTCPink: ENZC) closed down -3.01% to $0.1160 in the last trading session. A total of 13.98M shares exchanged hands during the session, with the price of Enzolytics stock ranging from $0.1140 to $0.1220. ENZC stock dropped despite the discovery of new target sites on HTLV-1 that was announced yesterday.

In what way did that discovery occur?

In addition to developing proprietary medicines to treat debilitating infectious diseases, Enzolytics is committed to commercializing its products worldwide. ITV-1 is ENZC’s patented treatment for HIV/AIDS, which uses inactivated pepsin fraction (IPF) as a suspension. Additionally, ENZC is the only company developing a proprietary technology for producing monoclonal antibodies (mAbs) for treating infectious diseases like HIV, rabies, influenza A, influenza B, tetanus, and diphtheria.

In an industry first, Enzolytics revealed yesterday that it has identified conserved, immutable sites on the HTLV-1 virus that it is targeting with monoclonal antibodies (mAbs).

• The HTLV-1 virus is not a vaccine target, nor are there current antiviral drugs that are effective against the virus.
• A conserved target site has now been identified using ENZC’s proprietary Artificial Intelligence (AI) methodology.
• At the Institute for Preclinical Studies at Texas A&M University, ENZC plans to manufacture human monoclonal antibodies against these target sites.
• A team from ENZC is attempting to identify critical sites on viruses that monoclonal antibodies will target to treat infectious viral diseases using Artificial Intelligence.
• Multi-targeted monoclonal antibodies targeting a range of conserved sites are crucial for an effective treatment strategy according to ENZC’s experts.
• EnZC is thus able to administer a “cocktail” of antibodies aimed at conserved and expectedly immutable targets.

How will ENZC excel in the future?

ENZC has now developed a comprehensive platform to produce numerous monoclonal antibodies targeting various pathogens. In ENZC’s platform, multiple conserved and expected to remain immutable sites on viruses are first identified and then fully human monoclonal antibodies that target those sites are produced. By using this approach, Enzolytics (ENZC) can tackle innumerable infectious diseases in humans with new and durable treatments.